Literature DB >> 335171

The eosinophil.

P B Beeson, D A Bass.   

Abstract

Mesh:

Substances:

Year:  1977        PMID: 335171

Source DB:  PubMed          Journal:  Major Probl Intern Med        ISSN: 0090-6956


× No keyword cloud information.
  8 in total

Review 1.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Rojelio Mejia; Thomas B Nutman
Journal:  Semin Hematol       Date:  2012-04       Impact factor: 3.851

Review 2.  New properties and roles for eosinophils in disease: discussion paper.

Authors:  C J Spry
Journal:  J R Soc Med       Date:  1985-10       Impact factor: 5.344

3.  Activation and release of enzymes and major basic protein from guinea pig eosinophil granulocytes induced by different inflammatory stimuli and other substances. A histochemical, biochemical, and electron microscopic study.

Authors:  H Popper; G Knipping; B M Czarnetzki; R Steiner; G Helleis; H Auer
Journal:  Inflammation       Date:  1989-04       Impact factor: 4.092

4.  Human eosinophils stimulate DNA synthesis and matrix production in dermal fibroblasts.

Authors:  T P Birkland; M D Cheavens; S H Pincus
Journal:  Arch Dermatol Res       Date:  1994       Impact factor: 3.017

Review 5.  Evaluation and differential diagnosis of marked, persistent eosinophilia.

Authors:  Thomas B Nutman
Journal:  Immunol Allergy Clin North Am       Date:  2007-08       Impact factor: 3.479

6.  Formation of Charcot-Leyden crystals by human basophils.

Authors:  S J Ackerman; G J Weil; G J Gleich
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

7.  Reply to Farmakiotis et al.

Authors:  Claire S Waddington; Thomas C Darton; Brian Angus; Andrew J Pollard
Journal:  Clin Infect Dis       Date:  2014-07-30       Impact factor: 9.079

Review 8.  Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.

Authors:  David J Jackson; Stephanie Korn; Sameer K Mathur; Peter Barker; Venkata G Meka; Ubaldo J Martin; James G Zangrilli
Journal:  Drug Saf       Date:  2020-05       Impact factor: 5.606

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.